why choose us

First received: February 14, 2023

Clinical Trial: Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age

Study Status: Completed

Recruit Status: RECRUITING

Condition: Allergy, Peanut

Study Type: INTERVENTIONAL


Official Title: A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of Epicutaneous Immunotherapy With DBV712 250 ?g in 4-7-year-old Children With Peanut Allergy (VITESSE)

Brief Summary: The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month treatment period.

Read more